Sr. Research Associate

Curtis Engelhart completed his Bachelor of Science in Chemistry at North Dakota State University in Fargo in 2009, and completed a Master of Science in Medicinal Chemistry at the University of Minnesota in Minneapolis in 2012. He spent one year working at GlaxoSmithKline in Tres Cantos, Spain, to develop a targeted whole-cell screen for inhibitors of biotin protein ligase from Mtb. In February 2014 he joined Dirk Schnappinger’s lab. His current work focuses on early drug discovery and target validation of drug candidates in development from various academic and industrial collaborative partners via chemical susceptibility profiling of Mtb conditional knock-down mutants (in single- and mixed-strain formats) and isolation/characterization of resistant Mtb mutants. In his free time Curtis enjoys hiking, cycling, video gaming, and hanging out with his pets, Charlie the cat and Hulk the dog.

Publications:

Beites, T.; O’Brien, K.; Tiwari, D.; Engelhart, C.A.et al. Plasticity of theMycobacterium tuberculosisRespiratory Chain and Its Impact on Tuberculosis Drug Development. Nat. Commun.2019, 10, 4970.

Bockman, M. R.; Engelhart, C. A.et al. Investigation of (S)-(–)-Acidomycin: A Selective Antimycobacterial Natural Product that Inhibits Biotin Synthase.ACS Infect. Dis.2019, 5, 598–617.

Bockman, M. R.; Engelhart, C. A.et al. Avoiding Antibiotic Inactivation in Mycobacterium tuberculosisby Rv3406 through Strategic Nucleoside Modification. ACS Infect. Dis. 2018, 4, 1102–1113.

Neres, J. P.; Engelhart, C. A.et al. Non-nucleoside Inhibitors of BasE, An Adenylating Enzyme in the Siderophore Biosynthetic Pathway of the Opportunistic Pathogen Acinetobacter baumannii. J. Med. Chem. 2013, 56, 2385–2405.

Engelhart, C. A.; Aldrich, C. C. Synthesis of Chromone, Quinolone, and Benzoxazinone Sulfonamide Nucleosides as Conformationally Constrained Inhibitors of Adenylating Enzymes Required for Siderophore Biosynthesis. J. Org. Chem. 2013, 78, 7470–7481.